NorthShore is one of 30 sites throughout the country participating in these randomized, double-blind, controlled, phase II trials and is the only site in the state of Illinois. The research is being funded by the U.S. Department of Defense and the National Institutes of Health.

Currently, only hospitalized patients have access to convalescent blood plasma for treatment of COVID-19.

"We are excited to be a part of this important research," said Giselle Mosnaim, MD, who is leading the studies at NorthShore. "These studies will give us the clinical data necessary to determine if convalescent blood plasma therapy can prevent infection and help patients recover more quickly in the early stages of the disease."